---
title: "Tremfya (guselkumab) in plaque psoriasis: Pharmacology questions"
description: "Pharmacology questions on Tremfya (guselkumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism and Pharmacokinetics. Questions: Does Tremfya lower IL-17 and IL-22 levels in plaque psoriasis? What is the half-life of Tremfya? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/pharmacology"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Tremfya (guselkumab) in plaque psoriasis: Pharmacology questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Tremfya](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf)

Pharmacology questions that apply to every indication of Tremfya are on [Tremfya (guselkumab), all indications: Pharmacology](https://www.evicenter.com/medical-information/tremfya/pharmacology).

## Mechanism

<a id="tremfya-il-17-levels"></a>

### Does Tremfya lower IL-17 and IL-22 levels in plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “In evaluated adult subjects with moderate-to-severe plaque psoriasis, guselkumab 
> reduced serum levels of IL-17A, IL-17F and IL-22 relative to pre-treatment levels 
> based on exploratory analyses of the pharmacodynamic markers.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

> “The relationship between these pharmacodynamic markers and the mechanism(s) 
> by which guselkumab exerts its clinical effects is unknown.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

## Pharmacokinetics

<a id="tremfya-half-life"></a>

### What is the half-life of Tremfya?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Apparent clearance in adult subjects with plaque psoriasis was 0.516 L/day. Mean 
> half-life of guselkumab was approximately 15 to 18 days in subjects with plaque 
> psoriasis across trials.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

## Related pages
- [Medical information: Tremfya (guselkumab): Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/guidelines)
